Whole Genome Sequencing Market to Reach New Heights by 2030
BOSTON, Aug. 13, 2025 /PRNewswire/ — According to the latest study from BCC Research, 'Whole Genome Sequencing: Global Markets' is projected to grow from $3 billion in 2025 to $6.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 15.1% from 2025 to 2030.
This report provides insights into the current and future market potential of whole genome sequencing (WGS), with global and regional projections through 2030. It includes market estimates by product and service type, covering instruments, consumables, and services. The workflow is segmented into pre-sequencing, sequencing, and data analysis. End users include research institutes, hospitals and clinics, pharmaceutical companies, and others. Applications span infectious diseases, cancer research, rare genetic diseases, and pharmacogenomics. The report also breaks down data by four regions: North America, Europe, Asia-Pacific, and the Rest of the World.
This report is particularly relevant today because whole genome sequencing (WGS) is emerging as a powerful tool for diagnosing, treating, and monitoring conditions like cancer, rare inherited disorders, and neurological diseases. Its ability to provide comprehensive genomic information helps reduce reliance on single-gene tests or invasive procedures. WGS is also increasingly used in drug development to identify better disease targets and select suitable patients for clinical studies through genomic profiling.
The factors driving the market's growth include:
Research on Cancer Genomics and Rare Inherited Diseases: Whole genome sequencing is vital for identifying genetic mutations linked to cancer and rare diseases. It enables faster, more accurate diagnoses and helps researchers develop targeted treatments by understanding disease mechanisms at the genetic level.
Falling Genome Sequencing Costs: Due to technological advances, the cost of sequencing a genome has dropped significantly, making it more accessible for clinical and research use. This affordability is expanding its adoption across the healthcare, biotech, and academic sectors.
Focus on Targeted Therapies and Personalized Medicine: WGS supports personalized medicine by revealing genetic profiles that guide treatment decisions. It helps tailor therapies to individual patients, improves drug response, and enables early disease detection and prevention strategies.
Request a sample copy of the global market for whole genome sequencing report.
Report Synopsis
Report Metric
Details
Base year considered
2024
Forecast period considered
2025-2030
Base year market size
$2.6 billion
Market size forecast
$6.1 billion
Growth rate
CAGR of 15.1% from 2025 to 2030
Segments covered
Product and Service Type, Workflow Type, Application, End User and Region
Regions covered
North America, Europe, Asia-Pacific and the Rest of the World (RoW)
Countries covered
The U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, India, South Korea, Australia, Rest of Europe, Rest of Asia-Pacific, South America, the Middle East and Africa
Market drivers
• Research on cancer genomics and rare inherited diseases.
• Falling genome sequencing costs.
• Focus on targeted therapies and personalized medicine.
Interesting facts:
The growing focus on personal genomics and prenatal testing drives the market's growth across all regions.
WGS-based diagnostics lead to more precise diagnosis and enable personalized treatment for each patient.
The report addresses the following questions:
What are the projected size and growth rate of the market?– The global EGS market was valued at $2.6 billion in 2024 and is expected to reach $6.1 billion by the end of 2030 at a CAGR of 15.1%.
Which factors are driving the growth of the market?– The increasing research on cancer genomics and rare inherited diseases and the growing focus on personalized medicine.
What are the key challenges and opportunities of the market?– Data analysis challenges and lack of infrastructure in emerging markets will challenge market growth during the forecast period.– The growing role of whole genome sequencing (WGS) in drug development and the increasing government initiatives to promote it create market opportunities.
Which market segments are covered in the report?– The market is segmented based on product and service type, workflow, application, end user and region. Product and service types include consumables, instruments, and services. Consumables are further segmented into library preparation kits, reagents and accessories.– Workflow sub-segments include pre-sequencing, sequencing, and data analysis. End users include research institutes, hospitals and clinics, and pharmaceutical companies. Applications include infectious diseases, cancer research, rare genetic diseases, and pharmacogenomics. The market is segmented by geographical region into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. Asia-Pacific includes China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific. The Rest of the World (RoW) includes South America, the Middle East and Africa. It includes global revenue ($ Million) for the base year of 2024 and estimated data for the forecast period 2025 through 2030.
Which product type will be dominant through 2030?– Consumables segment will dominate the market through the forecast period.
Which region has the highest market share?– North America accounted for a 50.9% share of the market in 2024.
Related reports:
Global Microbiome Sequencing Market: The report analyzes the microbiome sequencing market, segmenting it by component, sequencing technology, laboratory type, application, and end user. It explores trends, market drivers, restraints, and opportunities, along with macroeconomic influences and regulatory developments. The study also highlights technological innovations, patent activity, ESG factors, and competitive dynamics, including profiles of leading companies. Regions covered include North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, providing a global perspective on market growth and challenges.
Global DNA Sequencing: Research, Applied and Clinical Markets: This report presents an in-depth analysis of the DNA sequencing market, focusing on its status and future potential. It explores market drivers, restraints, and opportunities, along with competitive dynamics and product offerings. The market is segmented by technology (NGS, TGS, pyrosequencing, and Sanger sequencing), product and service types, end users, applications, and disease categories. It also includes company profiles with financials, product portfolios, and recent developments. Geographically, the report covers North America, Europe, Asia-Pacific, and the Rest of the World, offering a global perspective on market trends and forecasts.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo – https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/whole-genome-sequencing-market-to-reach-new-heights-by-2030-302528928.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
28 minutes ago
- Malaysian Reserve
Ultima Genomics' ppmSeq™ Delivers Unmatched Combination of Sensitivity and Efficiency for Whole-Genome MRD Detection
New bioRxiv paper showcases: Tumor-informed ctDNA detection down to one-in-ten million (10-7), which extends well beyond the limits of currently available clinical minimal residual disease (MRD) assays Superior double-stranded DNA (dsDNA) recovery rates versus other technologies, reducing sequencing requirements by 10- to 100-fold to achieve ultrasensitive detection levels and enabling a cost-effective whole-genome approach High efficiency and simple WGS workflow, yielding greater than 20x coverage per ng of cfDNA, reducing the amount of input material required for MRD and other liquid biopsy applications New highly sensitive approach to tumor-informed MRD as well as tumor-naive MRD and monitoring settings, where matched tumor tissue is not available FREMONT, Calif., Aug. 14, 2025 /PRNewswire/ — Ultima Genomics, a developer and manufacturer of an innovative ultra-high throughput sequencing architecture, announced a new publication, made available today in bioRxiv, showing the ultra-sensitive single-nucleotide variant (SNV) detection capabilities of its ppmSeq™ technology, with error rates down to 8 x 10-8. Led by researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center, this pre-print also demonstrates ctDNA detection limits for ppmSeq which significantly extends beyond the limits of currently available MRD assays, while utilizing a simple whole genome sequencing workflow that requires 10- to 100-fold less sequencing coverage versus other error correction techniques. These researchers conclude that these key features make ppmSeq well suited for clinical applications where high accuracy is required for mutation identification, such as tumor informed and tumor agnostic MRD detection. 'With its unique combination of low-cost and high accuracy, ppmSeq marks a real breakthrough in sequencing technology,' said Dan A. Landau, MD, PhD, a core member at the New York Genome Center, and Professor of Medicine & Professor of Physiology and Biophysics at Weill Cornell Medicine. 'It opens new horizons in studying the somatic genome as a novel frontier in human genetics, and holds enormous promise for clinical applications, including sensitive detection of cancer residual disease.' While high-throughput sequencing has seen rapid adoption for genome-wide variant identification, distinguishing true biological variation in the form of SNVs from sequencing errors remains a key challenge. Traditional sequencing approaches are too error-prone for detection of low variant allele frequency variants and are blind to errors resulting from DNA degradation or damage during sample preparation. These challenges limit the ability of traditional NGS technologies to detect and identify rare variants, a feature which is important in emerging applications like MRD and somatic mosaicism. To increase the ability to detect rare variants, current NGS approaches often rely on error-correction techniques, such as duplex sequencing, which involves sequencing both strands of a DNA molecule to filter out errors identified by discordant strands caused by single-stranded damage. While this reduces SNV error rates for dual-stranded reads, singleton reads must be discarded for these methods. As such, these methods require massive over sequencing to reliably capture sufficient duplex molecules, making whole-genome duplex sequencing prohibitively expensive. In a Nature Methods paper published in 2025, researchers in the Landau Lab demonstrated the advantages identifying SNVs with Ultima's flow-based sequencing by synthesis technology versus conventional SBS chemistry. Researchers identified that the ultra-low error profiles of Ultima's flow-based sequencing chemistry presented a foundation on which to build error correction techniques using duplex sequencing that could potentially enable ultra-low ctDNA detection levels, meaningful for applications that require rare mutation detection like MRD. In this new bioRxiv paper, researchers from the same group utilized ppmSeq, a technology developed by Ultima and native to the Ultima platform, to further improve upon the previously published low SNV detection limits. Building on Ultima's ultra-low error, flow-based sequencing, ppmSeq encodes both strands of DNA molecules in a single sequencing read to enable up to part-per-ten million (10-7) accuracy (SNVQ70) for SNV calling. This exceptional accuracy provides extreme assay sensitivity for low frequency alleles while also requiring 10- to 100-fold less sequencing depth than other error correction techniques. Study showcases ppmSeq as a highly accurate, low-cost, high throughput method for dsDNA sequencing built on a simple WGS workflow with potential for robust clinical applications Researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center benchmarked ppmSeq assay performance and sensitivity against other technologies. Key findings demonstrate ppmSeq has: Ultrasensitive SNV detection capabilities. ppmSeq demonstrated ultrasensitive SNV detection with error rates down to 0.8 x 10-7 (0.8 parts-per-ten million) for gDNA and cell-free DNA. Superior dsDNA recovery rates and lower sequencing requirements. ppmSeq demonstrated superior double-stranded DNA (dsDNA) recovery rates, reducing sequencing requirements by 10- to 100-fold and enabling a cost-effective whole genome approach. Ability to sequence low-input samples. The ppmSeq workflow was shown to be highly efficient, yielding greater than 20x coverage per ng of cfDNA and reducing the amount of input material required. Researchers also tested the capabilities of ppmSeq in clinical applications by assessing circulating tumor DNA (ctDNA) detection for disease monitoring in cancer patients. Key findings include: Tumor-informed ctDNA detection down to one-in-ten million. ppmSeq enabled tumor-informed ctDNA detection of 10-5 across multiple cancers, and up to 10-7 in cancers with high mutation burden at 30x sequencing depth, which extends below the limits of current MRD assays. ctDNA detection capabilities in tumor-naive disease monitoring. ppmSeq identified disease-specific signal in plasma cell-free DNA without the need for a matched tumor. Together, these researchers conclude that ppmSeq is a highly accurate and cost-effective option for emerging clinical applications including tumor-informed MRD, tumor-naïve MRD and an opportunity to explore new whole-genome applications in cancer genomics, including somatic mosaicism. 'As a highly accurate, highly scalable WGS approach, ppmSeq can be a key building block for the next generation of tumor-informed and tumor-naive cancer monitoring applications' said Adam Widman, MD, a researcher and medical oncologist at Memorial Sloan Kettering Cancer Center and a co-author on the study. 'ppmSeq is a major step forward in high-accuracy sequencing,' said Charles Swanton, Deputy Clinical Director at The Francis Crick Institute. 'Its low error rate and high throughput could enable powerful new applications in liquid biopsy and beyond. This study showcases how ultra-low error, high-throughput sequencing with ppmSeq could transform applications in the field of MRD requiring very high accuracy — from bench to bedside.' Ultima's ppmSeq technology enables high-quality data and its published specifications provide part-per-million accuracy, or SNVQ60, for calling single nucleotide variants (SNVs). ppmSeq, designed for the UG 100 sequencing platform, is also compatible with the UG 100 Solaris Free workflow. Launched at AGBT 2025, the UG 100 Solaris workflows enabled an over 50% increase versus prior specifications in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome. 'Ultima's unique sequencing architecture was designed to specifically meet the needs of cost-effective, large-scale applications. It especially excels in applications like liquid biopsy that require extreme accuracy, and we are excited to see further validation of ppmSeq within the academic community,' said Gilad Almogy, CEO and Founder of Ultima Genomics. 'We believe that sensitivity, ease of workflow and low cost of ppmSeq will be transformational for applications requiring earlier detection such as MRD.' The full study, 'Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules' is now available in bioRxiv. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Media Contact Vikki Herrera for Ultima Genomics408-206-7009vikki@
Malaysian Reserve
38 minutes ago
- Malaysian Reserve
FirstService Residential Earns WELL Certified™ Gold for South Region Headquarters
Company commemorates workplace excellence milestone with an immersive wellness event for associates in their South Region headquarters in Florida PLANTATION, Fla., Aug. 14, 2025 /PRNewswire/ — FirstService Residential, North America's leading residential property management company, announced today that its South Region headquarters has achieved WELL Certified™ Gold from the International WELL Building Institute. The recognition is awarded to spaces that prioritize health, safety, and well-being through measurable performance criteria and reflects FirstService Residential's commitment to cultivating employee-centered workplaces. To celebrate the milestone, the company hosted a wellness event yesterday, August 13, at its South Region headquarters. The day began with a live unveiling of the WELL Certified™ Gold seal by Debra George, Vice President of Operations of the company's South Region. In-person activities included chair yoga, sound bath sessions, nutrition education, tours, and a 'Build Your Own Healthy Bento Box' station for lunch. Each activation helped associates connect WELL principles to their daily routines in the office. 'Achieving WELL Certified™ Gold reflects our commitment to creating workplaces that support our associates' health and wellness,' said Robert G. Smith, President, South Region. 'This recognition underscores our belief that when our associates thrive in the workplace, they're better equipped to deliver exceptional support to the residents and communities we are proud to serve.' WELL Certification is based on attaining exceptional levels of quality in criteria including air and water quality, natural light, ergonomic workspace design, mental health support, and nutrition-focused amenities. This achievement reflects a shared effort between FirstService Residential and FirstService Energy, the company's energy advisory affiliate, to design a workplace that supports well-being in real, lasting ways. 'FirstService upholds the same wellness standards in our workspaces that we help residents and communities achieve in their homes,' said Paula Allen, Senior Vice President of Human Resources, South Region. 'Earning this certification required meeting strict criteria across all aspects of our work environment, which reflects the company's deep commitment to creating spaces where our team members can excel daily.' The WELL Certified™ Gold achievement adds to a growing list of workplace honors for FirstService Residential. The company was recently named to Newsweek's 2025 list of America's Greatest Workplaces for Mental Well-Being and earned repeated recognition from Great Place to Work® in the United States and Canada. These achievements reflect the company's belief that investing in associate well-being leads to stronger teams, better service, and thriving communities. About FirstService ResidentialFirstService Residential is simplifying property management. Its hospitality-minded teams serve residential communities across the United States and Canada. The organization partners with boards, owners, and developers to enhance the value of every property and the life of every resident. Leveraging unique expertise and scale, FirstService serves its clients with proven solutions and a service-first philosophy. Residents can count on 24/7 customer care and tailored lifestyle programming, amenity activation, and technology for their community's specific needs. Market-leading programs with FirstService Financial, FirstService Energy, and special districts teams deliver additional levels of support. Boards and developers select FirstService Residential to realize their vision and drive positive change for residents in the communities in their trusted care. FirstService Residential is a subsidiary of FirstService Corporation (NASDAQ and TSX: FSV), a North American leader in providing essential property services to a wide range of residential and commercial clients.
Malaysian Reserve
42 minutes ago
- Malaysian Reserve
InventHelp Inventors Develop New Device to Store and Access Wet Wipes (PTA-378)
PITTSBURGH, Aug. 14, 2025 /PRNewswire/ — 'We wanted to create an improved way to access wet wipes for increased sanitation when using the bathroom,' said an inventor, from Bellevue, Wash., 'so we invented the CLEAN ROLL. Our design could contribute to better hygiene techniques, and it prevents the wet wipes from drying out.' The invention provides an improved way to store and access wet wipes for maximum cleanliness when using the bathroom. In doing so, it offers an alternative to using dry toilet tissue alone or traditional wipes that dry out. As a result, it increases personal hygiene. It also helps reduce irritation, bad odors, dryness, etc. The invention features a refillable design that is easy to use so it is ideal for households. The original design was submitted to the Portland sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-PTA-378, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at
